Suraksha Diagnostic profit and loss

Latest FY26

Revenue: ₹310cr+23.1% on FY25
EBITDA: ₹95.4cr+17.4% on FY25
Net profit: ₹31.4cr+1.4% on FY25
EPS: ₹6.18+3.5% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Jun 2026	FY26Mar 2026	FY25Mar 2025

Expenses
	325	310	252
	3.3	3.2	3.8
	329	314	256
	37.7	36.5	29.5
	54.9	53.3	42.9
	13.6	12.6	8.4
	43.2	41.4	35.3
	131	125	98.4
	280	269	215
	102	95.4	81.2
	58.8	53.9	45.9
Profit
	48.6	44.6	41.4
	48.6	44.6	41.4
	12.1	10.8	10.3
	1.4	2.4	0.1
	13.5	13.2	10.4
	35.1	31.4	31.0
	35.1	31.4	31.0
	0.5	0.6	−0.2
	35.6	32.0	30.8
	35.8	32.2	31.8
	−0.7	−0.8	−0.8
Per share
	₹6.88	₹6.18	₹5.97
	₹6.88	₹6.18	₹5.97
Other comprehensive income — detail
	0.5	0.6	−0.2
	0.5	0.6	−0.2
	36.3	32.8	31.6
	−0.7	−0.8	−0.8
Per share — as-filed variants
	₹6.88	₹6.18	₹5.97
	₹6.88	₹6.18	₹5.97
Derived — gross profit (revenue − materials − purchases − Δ inventories)
	288	274	223
	88.4%	88.2%	88.3%
Adjusted (ex-exceptional items) — derived
	48.6	44.6	41.4
	35.1	31.4	31.0
	₹6.88	₹6.18	₹5.97

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

SURAKSHA₹300.45

Suraksha Diagnostic Limited

· Pharma & Health

Annual Quarterly₹ CrorePeersKRSNAA HEALTHX NEPHROPLUS 3BBLACKBIOMcap ₹1,565 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/06/2026
Revenue from Operations	252.1	310.4	325.5
Other Income	3.8	3.2	3.3
Total Income	255.9	313.6	328.8
Expenses
+ Cost of Materials Consumed	29.5	36.5	37.7
+ Employee Benefit Expense	42.9	53.3	54.9
+ Finance Costs	8.4	12.6	13.6
+ Depreciation & Amortisation	35.3	41.4	43.2
+ Other Expenses	98.4	125.3	130.8
Total Expenses	214.5	269.0	280.2
EBITDA	81.2	95.4	102.1
EBIT	45.9	53.9	58.8
Profit
PBT before Exceptional Items	41.4	44.6	48.6
Pretax Income	41.4	44.6	48.6
+ Current Tax	10.3	10.8	12.1
+ Deferred Tax	0.1	2.4	1.4
Tax Expense	10.4	13.2	13.5
Net Income	31.0	31.4	35.1
+ Net Income — Continuing Ops	31.0	31.4	35.1
+ Other Comprehensive Income	-0.2	0.6	0.5
Total Comprehensive Income	30.8	32.0	35.6
Net Income to Common	31.8	32.2	35.8
Minority Interest	-0.8	-0.8	-0.7
Per Share
Basic EPS	5.97	6.18	6.88
Diluted EPS	5.97	6.18	6.88
Other Comprehensive Income — detail
+ Other Comprehensive Income	-0.2	0.6	0.5
+ Items NOT to be Reclassified to P&L	-0.2	0.6	0.5
Comprehensive Income — Owners of Parent	31.6	32.8	36.3
Comprehensive Income — Non-controlling Interests	-0.8	-0.8	-0.7
Per Share — as-filed variants
Basic EPS — Continuing Operations	5.97	6.18	6.88
Diluted EPS — Continuing Operations	5.97	6.18	6.88
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit	222.6	273.9	287.8
Gross Margin %	88.29	88.25	88.41
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)	41.4	44.6	48.6
Net Income Adj (tax-effected)	31.0	31.4	35.1
EPS Adj	5.97	6.18	6.88
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value	2.00	2.00	2.00
Paid Up Equity Capital	10.4	10.4	10.4

As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.